Related Experiment Video

Updated: Aug 10, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Strategy and planning for chemopreventive drug development: clinical development plans II

G J Kelloff1, J A Crowell, E T Hawk

  • 1Division of Cancer Prevention and Control (DCPC), National Cancer Institute (NCI), Bethesda, MD 20892, USA.

Journal of Cellular Biochemistry. Supplement
|January 1, 1996
PubMed

Insights

This publication details the development plans for 16 promising chemopreventive agents, outlining their safety, efficacy, and future research strategies for cancer prevention. These plans aim to advance novel cancer-fighting drugs through rigorous scientific evaluation.

Area of Science:

  • Oncology
  • Pharmacology
  • Preventive Medicine

Background:

  • The National Cancer Institute's Chemoprevention Branch and Agent Development Committee publish Clinical Development Plans (CDPs) to track promising cancer-preventive agents.
  • These CDPs consolidate evidence on the safety and efficacy of chemopreventive agents from preclinical and clinical studies.

Purpose of the Study:

  • To summarize the current status and outline future development strategies for 16 novel chemopreventive agents.
  • To stimulate scientific interest and discussion regarding the development of new generations of cancer chemoprevention drugs.

Main Methods:

  • Summarizing preclinical and clinical data on safety and efficacy for each agent.
  • Detailing strategies for further drug development, including pharmacodynamics, biomarker identification, toxicity assessment, and clinical trial design.

Main Results:

  • Presents 16 detailed Clinical Development Plans for agents including curcumin, folic acid, genistein, sulindac sulfone, and various retinoids.
  • Provides a comprehensive overview of the evidence supporting the chemopreventive potential of these agents.

Conclusions:

  • The published development plans offer a strategic roadmap for advancing chemopreventive agents towards clinical application.
  • Encourages further research and collaboration within the scientific community to accelerate the development of effective cancer prevention strategies.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...